key: cord-0875871-kv9eqet1
authors: SATUE-GRACIA, E. M.; Vila-Corcoles, A.; De Diego-Cabanes, C.; Vila, A.; Torrente-Fraga, C.; Gomez-Bertomeu, F.; Hospital-Guardiola, I.; Ochoa-Gondar, O.; Martin-Lujan, F.
title: Susceptibility and risk of suffering SARS-COV-2 infection by demographic characteristics and pre-existing medical conditions among middle-aged and older adults in Tarragona, Spain: results from the COVID19 TARRACO Cohort Study, March-June 2020
date: 2021-02-10
journal: nan
DOI: 10.1101/2021.02.09.21251398
sha: 8e30e9a7e9e418cb942ef0e67a53d4c3e0da96e4
doc_id: 875871
cord_uid: kv9eqet1

Objective: To analyse susceptibility/risk of suffering COVID19 among adults with distinct underlying medical conditions. Methods: Cohort study (population-based) including 79,083 people >=50 years-old in Tarragona (Southern Catalonia, Spain). At study start (01/03/2020) baseline cohort characteristics (demographic, previous comorbidities, chronic medications and vaccinations history) were recorded. Primary outcome was laboratory-confirmed COVID19 incurred in cohort members throughout 01/03/2020-30/06/2020. Risk of suffering COVID19 was evaluated by Cox regression, estimating multivariable hazard ratios (HRs) adjusted for age/sex and previous comorbidities. Results: Across study period, 536 laboratory-confirmed COVID19 cases were observed (mean incidence: 39.5 cases per 100,000 persons-week). In multivariable-analysis, age/years (HR: 1.01; 95% CI: 1.00-1.02; p=0.050), nursing-home (HR: 20.19; 95% CI: 15.98-25.51; p<0.001), neurological disease (HR: 1.35; 95% CI: 1.03-1.77; p=0.029), taking diuretics (HR: 1.39; 95% CI: 1.10-1.75; p=0.006), antiplatelet (HR: 1.36; 95% CI: 1.05-1.76; p=0.021) and benzodiazepines (HR: 1.24; 95% CI: 1.00-1.53; p=0.047) significantly increased risk; while smoking (HR: 0.57; 95%CI: 0.41-0.80; p=0.001), angiotensin converting enzyme inhibitors (HR: 0.78; 95% CI: 0.61-1.00; p=0.048), angiotensin II receptor blockers (HR: 0.70; 95%CI: 0.51-0.96; p=0.027) and statins (HR: 0.75; 95% CI: 0.58-0.96; p=0.025) were associated with reduced risk. Among non-institutionalised persons, cancer, renal and cardiac disease appeared also related to increased risk, whereas influenza vaccination was associated with reduced risk. Conclusion: In a setting with relatively low incidence of COVID19 across the first wave of pandemic period, age, nursing-home residence and multiple comorbidities appear predisposing for COVID19 among middle-aged/older adults. Conversely, statins, angiotensin-receptor blockers/inhibitors and influenza vaccination were related with decreased risk. KEYWORDS: Coronavirus; SARS-COV-2; COVID19; Incidence; Risk.

The novel severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), discovered in December 2019 following an outbreak of pneumonias in Wuhan, China, causes an infectious illness known as coronavirus disease 2019 (COVID19).

The World Health Organisation (WHO), due to the alarming levels of spread of the disease and its severity, declared it to be a pandemic on March 11, 2020. [1] Currently the disease continues to spread in the world, with almost 100 million confirmed cases in later January 2021. [2] In Spain there was a first wave in March-April that was considered contained on May 11, with a total of just over 250,000 diagnosed cases; the contagion curve grew again in June until reaching the maximum peak of second wave in mid-October and as of later January 2021, in the middle of the third wave, the Spanish Ministry of Health reports 2,705,001 cases and almost 58,000 deaths. [3] There is much information updating COVID19 surveillance epidemiological data (number of cases and deaths by demographic characteristics, accumulated incidences, ratios for positive laboratory testing, etc.); but there is few populationbased data on specific incidence and susceptibility for SARS-COV-2 infection in population subgroups with distinct underlying -believed as at-risk-conditions. [2, 3] Earlier studies regarding clinical characteristics and prevalence of comorbidities among COVID19 patients reported that cardiovascular disease (including hypertension), chronic respiratory disease, renal disease, cancer, diabetes mellitus, obesity and smoking were major risk factors for severe COVID19. However, most of these results (mainly based on hospitalised severe cases) are likely confounded by age and other unadjusted variables (including else socio-demographic, medical or health care-related factors). [4] [5] [6] [7] Of note, COVID19 patients managed as outpatients were generally poorly represented in COVID19 research studies. [4] [5] [6] [7] In this sense, a UK report based on a primary care cohort found that positive SARS-COV-2 testing was associated with similar risk factors (except smoking) as described for severe COVID19 in hospital settings.

[8] Nevertheless, there is uncertainty about the possibility that some of these conditions, although they increase the risk of severe COVID19, may not "per se" increase the risk of SARS-COV-2 infection. [9] In this context, we designed a large population-based retrospective-prospective cohort study (initiated in April 2020 and named as TARRACO Cohort Study) aimed to investigate the incidence, clinical characteristics, susceptibility and risk profile of suffering COVID19 among middle-aged and older adults (who supported the greatest burden of COVID19 at this time) in the region of Tarragona across pandemic period. chronic medication and vaccinations' history for cohort members in order to establish their baseline conditions (at March 1, 2020) .

At the COVID19 epidemic period onset in the area, two electronic alerts, linked to COVID19 laboratory tests results and ICD-10 codes for disease suspicion (B34.2 and B97.29), were added to the electronic clinical records system of PCCs.

Subsequently, both data sources were associated in the anonymised research database used for this report. Vital status for all cohort members was considered according to administrative data periodically updated in the electronic PCCs' clinical records.

The main outcome was laboratory-confirmed COVID19 diagnosed by reverse transcription-polymerase chain reaction (RT-PCR) or serological testing. For laboratory diagnosis of COVID19, guidelines of the Health Department of the Generalitat de Catalunya were implemented.

[15] Of note, the availability of PCR testing was scarce during the first weeks of epidemic period, and they were prioritised for severe cases (requiring hospital admission) and nursing-home residences (where several outbreaks took place); while less PCR tests were made among suspected cases with mild symptoms managed as outpatients. We report, in descriptive analysis, presumed COVID19 cases (people who presented clinical suspicion who were no PCR-tested) and, also, COVID19-excluded cases (with negative result in PCR-test) detected among cohort members across the study period. Cox regression analyses were used to calculate unadjusted, age&sex-adjusted and multivariable-adjusted hazard ratios (HRs) aimed at estimating the association between baseline exposure conditions and the time to the first outcome (laboratoryconfirmed COVID19) in cohort members throughout the study period (from 1st March to 30th June 2020). We included in exploratory multivariable Cox models all above . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2021. ; mentioned exposure and covariates (i.e., age, sex, residence, vaccinations' history, comorbidities/underlying conditions and medication use). The method to select a subset of variables to include in final models was the purposeful selection. [17] These models incorporate significant and confounder variables as well as all covariates judged clinically or epidemiologically relevant. We performed a main analysis with the total study cohort (N=79,083) and two subgroup analyses restricted to community-dwelling people (N=77,669) and nursing-home residents (N=1414).

Statistical significance was set at p <0.05 (two-tailed). Analyses were performed using IBM SPSS Statistics for Windows, version 24 (IBM Corp., Armonk, N.Y., USA). Total cohort members were followed for 1,356,358 persons-weeks (1, 335, 069 persons-weeks community-dwelling and 21,289 persons-weeks nursing-home residents).

Of the 79,083 cohort members, 4084 (5.2%) were PCR tested for SARS-COV-2 infection across the study. Of them, 3577 (87.6%) had a negative result and 507 (12.4%) had a positive result (319 community-dwelling and 188 nursing-home residents). Additionally, 29 cohort members had a positive laboratory serological testing for SARS-COV-2 (twenty-six community-dwelling and three nursing-home residents). In two hundred and eighty-three cohort members COVID19 was suspected (clinically compatible) but no laboratory test was performed.

Of the 536 laboratory-confirmed COVID19 cases, 235 (43.8%) were men and 301 (56.2%) women, with a mean age of 74 years (SD: 14.4). By age groups, 177 (33.0%) occurred in those who were 50-64 years, 137 (25.6%) in those 65-79 years and 222 (41.4%) in aged 80 years or more. Three hundred and forty-five cases (64.4%) occurred in community-dwelling and 191 (35.6%) in nursing-home residents. The most prevalent comorbidities were hypertension (54.1%), cardiac disease (28.5%), obesity (25.2%), diabetes (23.5%), respiratory disease (14.9%) and neurological disease (14.7%). Figure 1 shows weekly distribution of COVID19-confirmed cases and cumulative incidences at 7-days and 14-days across the 18 weeks of the study period.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2021. ; According to baseline chronic medications, maximum IRs (per 100,000p-w) appeared among those receiving diuretics (97.0), oral anticoagulants (87.3), insulin (83.1), and inhaled-respiratory therapy (72.1) ( Table 1) . Table 2 shows unadjusted, age&sex-adjusted and multivariable-adjusted analyses evaluating risk of suffering laboratory-confirmed COVID19 in the whole study cohort.

In the unadjusted analysis, many previous comorbidities and medications were associated with increased risk. However, after multivariable-adjustment, only age . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2021. 

Population-based clinical data on susceptibility and risk of SARS-COV-2 infection is limited. [9, 18] This large cohort study was aimed to assess population-based incidence of (laboratory-confirmed) COVID19 among middle-aged and older adults with distinct underlying medical conditions in a well characterised geographic area (Tarragona region) during the first wave of the COVID19 epidemic (March-June 2020); we investigated possible relationships between pre-existing medical conditions (including common comorbidities, vaccinations' history and chronic medication use) with the susceptibility/risk of suffering COVID19.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.09.21251398 doi: medRxiv preprint As main result, we found a mean IR of 39.5 laboratory-confirmed COVID19 cases per 100,000 persons-week thru study period, which is a relatively low incidence as compared to other Spanish or European regions during the same time period. [19, 20] .

During the study period (17.4 weeks since 1st March until 30th June 2020), approximately 5% of cohort members were PCR tested (with 12.4% positive results).

Taking this data into account, and considering that PCR test were scarcely available in the study area for patients with less severe symptoms during the first weeks of the epidemic period, the true incidence of COVID19 was logically underestimated.

Nevertheless, considering the relatively low number of presumptive cases (clinical suspicion alone without PCR performed), our data also suggests that the overall number of infected people was considerably lower than initially speculated (as showed by the national seroprevalence study).

[21] Assuming this relatively little incidence, we found that increasing age, nursing-home residence, some pre-existing comorbidities (cancer, neurological, renal or cardiac disease and taking certain chronic medications (diuretics, antiplatelet drugs and benzodiazepines) were independent factors related to increased risk of suffering COVID19. In contrast, cohort members receiving statins or ACEIs/ARBs (and, in the case of communitydwelling individuals, those vaccinated against influenza in prior autumn) presented, after multivariable adjustment, a decreased risk.

Of note, in the crude analyses several covariates (comorbidities, medications and vaccinations) appeared significantly associated with increased risk/susceptibility of suffering COVID19. However, for most of them the significance disappeared after age&sex-adjustment and only a few remained independently associated with an increased risk after multivariable adjustments. This highlights the importance of reporting adjusted data and note that differences in adjustment methods may explain, in part, the heterogeneous results (when evaluating the possible association between some pre-existing conditions and risk of COVID19) reported to date. [22] At present, there is not clear evidence about possible clinical predisposing and protecting factors front SARS-COV-2 infection, and uncertainty surrounds this issue.

[23]

If we consider demographic characteristics, apart from nursing-home residence that increased twenty-times the adjusted-risk of suffering laboratory-confirmed COVID19, we found that age increased approximately 1-2% for each year the adjusted-risk of suffering COVID19. While COVID19 was more frequent in women, sex did not alter significantly the risk of infection in multivariable analysis.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.09.21251398 doi: medRxiv preprint Considering pre-existing comorbidities, only neurological disease (basically patients with a history of dementia and/or stroke living in nursing-home residences) was associated with increased multivariable-adjusted risk of infection in the analysis of full cohort. Concomitantly, previous cancer, renal disease and cardiac disease emerged significantly associated with increased risk in subgroup analysis restricted to community-dwelling individuals.

In the present study, chronic respiratory disease, diabetes, hypertension and obesity did not emerge independently associated with significant increased risk of suffering laboratory-confirmed COVID19 after multivariable-adjusted analyses. There is general accordance considering these conditions as major risk factors for poor prognosis in hospitalised COVID19 patients, but there is few data assessing their role in predisposing for SARS-COV-2 infection. [24] Surprisingly, smokers presented the lowest specific incidence rate of COVID19 in the present report, and smoking was associated with a statistically significant reduced risk of COVID19, both in multivariable analyses evaluating the total study cohort and in the restricted to community-dwelling individuals. Notably, active smoking has been linked with decreased odds of a positive result SARS-CoV-2-test in other studies. [8] Opposite findings about poor prognosis among smokers with COVID19 have been reported. [25, 26] Considering chronic medication use, receiving diuretics, antiplatelet drugs and benzodiazepines appeared significantly associated with increased risk of suffering COVID19. In contrast, taking statins and ACEIs or ARBs emerged associated with decreased risk. At onset of COVID19 pandemic, after discovering that the host receptor for SARS-CoV-2 cell entry was the angiotensin-converting enzyme 2 (ACE2), it was feared that receiving ACEIs/ARBs could facilitate SARS-COV-2 infection and predispose to suffer severe COVID-19. However, most recent studies have concluded that there is no clinical or experimental evidence supporting that ACEIs or ARBs augment the susceptibility to/severity of COVID-19 at present. Indeed, ACEIs/ARBs have been associated with lower incidence and/or improved outcomes in patients with lower respiratory tract infections, and with lower risk of allcause mortality in COVID19 hospitalised patients. Our data also support this conclusion.

Considering statins, while first studies reported opposite results, our data showing a decreased risk of laboratory-confirmed COVID19 among people taking these drugs are in accordance with conclusions of a recent meta-analysis on this concern. [28]

Anyway, caution is recommended until further evidence emerges surrounding statin use in COVID19 patients.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.09.21251398 doi: medRxiv preprint Regarding other chronic medications that appeared associated with increased risk in the current study (i.e., diuretics, antiplatelet drugs and benzodiazepines), we have not a clear interpretation for this data. It is possibly due to an unresolved residual confounding, linked to unmeasured health-care-related factors or insufficient ageadjustment, but we also note that some of them (e.g., benzodiazepines) have already been reported associated with greater risk of pneumonia (common clinical manifestation in COVID19 patients).

Antihistamines' use was not associated with any statistically significant change in the risk of suffering COVID-19 in the present study. We note that antihistamines' use was associated (marginally significative) with a lower risk of COVID19 in an earlier report, [12] but we also remark that it could be due to an alpha error considering that this final report has greater statistical power (since include more persons-time followup and greater number of events analysed).

Similar to data observed in earlier analyses, we found that influenza vaccination in prior autumn was significantly associated with a reduction risk of suffering COVID19 among community-dwelling individuals.

[10] Conversely, it was associated with a greater risk in the subgroup of nursing-home residents (where a significant protective association appeared for those who had received tetanus vaccination). While these associations could be due to residual confounding related with unmeasured life-style or healthcare factors, further investigations are needed exploring a possible immunity-related mechanism explanation. [29, 30] Major strengths in this study were the representativity (due to large size) of the study cohort, that included almost 80,000 people, which represents about 75% of the entire population over 50 years in the area, [13] and the use of survival analysis to precisely asses susceptibility and risk of suffering a SARS-COV-2 infection adjusting by important potential confounders (as socio-demographic, and medical underlying conditions clinically relevant) Major limitations were related to its partially retrospective design and poor access to PCR tests at the beginning of the epidemic period in our setting, especially considering that the most specific diagnosis for COVID19 is a positive PCR test.

Moreover its reliability depends on the correct collection of nasopharyngeal swabs, moment of collection, sensitivity of tests and guidelines for testing followed throughout the study period. Due to above mentioned scarce availability of PCR tests they were mainly performed in hospitalised/severe patients and in nursing homes (after some outbreaks were detected). Thereby, patients with mild symptoms (many of them without PCR done) have been logically underestimated in this study.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Even though we did subgroup analyses (community-dwelling/nursing-home) and multivariable-adjustments, residual confounding when estimating risks (common in observational studies), tied to non-included variables such as socio-economical, labor-, lifestyle-or health care-related factors, may not be discarded.

Despite the large size of the cohort, there were relatively few events (536 laboratoryconfirmed COVID19 cases), which limits statistical power. This is especially relevant in the subgroup of nursing-home residents where, even if great incidence occurred (200 cases per 100,000 persons-week), only 191 confirmed COVID19 cases were detected, fact that largely affects the precision of estimates (confidence intervals very wide).

Notwithstanding all mentioned limitations, authors may emphasise the added value that provide adjustments (age&sex and multivariable), not present in many other studies. Their importance is clearly evident if we compare, for example in Table 3 and 5, crude with adjusted results.

Concerning external validity, we must consider that the study was conducted in a single geographic area; thus, specific incidence data cannot be directly extrapolated to other regions with distinct epidemic conditions. Nevertheless, we also note that the adjusted-risks estimated here may be helpful to better characterize the risk profile (socio-demographic, pre-existing conditions/comorbidities, chronic medication use) for suffering COVID19 among middle-aged and older adults living in a setting with low/moderate intensity of COVID19, as in the present study.

In summary, in this large population-based study that followed a cohort of 79,083 individuals ≥ 50 years old between March-June 2020 in Tarragona area, the incidence of laboratory-confirmed SARS-COV-2 infection was relatively low (39.5 cases per 100,000 persons-week) as compared with that of other Spanish regions during the first wave of COVID19 pandemic.

In this epidemic context (low incidence), our data support that increasing age, nursing-home residence, pre-existing cancer, neurological, renal and cardiac disease are independent major predisposing conditions to suffer COVID19 among middleaged and older adults. Patients receiving diuretics, antiplatelet drugs and benzodiazepines were also at increased risk. Oppositely, patients taking statins, rennin-angiotensin-aldosterone system inhibitors and those community-dwelling . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.09.21251398 doi: medRxiv preprint individuals that received influenza vaccination in prior autumn presented decreased risk.

This study was supported by a grant from the Instituto de Salud Carlos III of the Spanish Health Ministry (file COV20/00852; call for the SARS-COV-2/COVID-19 disease, RDL 8/2020, March 17, 2020).

ESG and AVC wrote the manuscript; CDC, CTF, FGB, and IHG obtained data; ESG and AVR assessed outcomes and did statistical analyses; AVR edited the manuscript; OOG and FML revised the final version; AVC coordinated the study.

This study is supported by a grant from the Instituto de Salud Carlos III of the Spanish Health Ministry (file COV20/00852; call for the SARS-COV-2/COVID19 disease, RDL 8/2020, March 17, 2020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

All authors, none declared.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.09.21251398 doi: medRxiv preprint 

Listings of WHO's response to COVID-19

Weekly epidemiological update-27

Centro de Coordinación de Alertas y Emergencias Sanitarias. Actualización nº 300

Association between COVID-19 prognosis and disease presentation, comorbidities and chronic treatment of hospitalized patients

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a crosssectional study

Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona

Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke

What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate and associated risk factors

Calidad e innovación. Centro de Coordinación de Alertas y Emergencias Sanitarias. Información científica-técnica

Instituto de Salud Carlos III. Estudio ENE-COVID19: informe final. Estudio nacional de seroepidemiología de la infección por SARS-CoV-2 en España

Centres for Disease Control and Prevention. Coronavirus Disease 2019 (COVID19)

SARS -CoV-2: Reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria and Bordetella pertussis)

Multivariable-adjusted HR (95% CI) p-value Socio-demographic Age (continuous years)

Cardiac disease 1.97 (1.63-2.37)

Chronic medication use Diuretics 2.95 (2.43-3.58)

Antiplatelet drugs 1.94 (1.57-2.39)

NOTE: HRs denotes Hazard ratios, and were calculated for those who had the condition as compared with those who had not the condition. In multivariable-adjusted analysis the HRs were adjusted for age (continuous years), sex, residence, comorbidities/underlying conditions and chronic medication use. CIs denote confidence intervals. Multivariable-adjusted HR (95% CI) p-value Socio-demographic Age (continuous years)

Chronic medication use Diuretics 2.22 (1.71-2.89)

Vaccination's history Flu vaccine in prior autumn

NOTE: HRs denotes Hazard ratios, and were calculated for those who had the condition as compared with those who had not the condition. In multivariable-adjusted analysis the HRs were adjusted for age (continuous years), sex, comorbidities/underlying conditions and chronic medication use

NOTE: p-values in univariate analysis were calculated by chi-squared, or Fisher's test as appropriate, comparing percentages in the study population vs COVID-19 cases; HRs denotes Hazard ratios, and were calculated for those who had the condition as compared with those who had not the condition, and were adjusted for age (continuous years), sex, comorbidities/underlying conditions and chronic medication use